Motivation
​​There remains a significant unmet need in getting transformational therapeutics for rare disease into the clinic. With more than 10,000 identified rare diseases, the need for innovative therapies has never been more urgent.
​
One of the immediate and key challenges in the rare disease field is the limited access to innovative technologies. These technologies are often locked behind exclusive licensing agreements or siloed within proprietary industry pipelines. This creates a significant barrier for patient families and foundations, who are eager to develop treatments, but lack the means to access or apply next-generation technologies.
​
Addressing the access gap is critical to the advancement of treatments for rare disease.
This is our mission.
Approach
The ATG project is a non-profit initiative (501(c)(3) organization) based on a unique model that enables access to gene therapy innovation. ATG is working to bring innovative therapeutic technologies from a versatile portfolio to patients by partnering with rare disease foundations, industry and academic researchers. Through matching these transformative technologies with corresponding patient communities, the ATG project aims to advance the development of therapeutics for rare disease.
​
